52 results about "Molecular pathology" patented technology

A process for the production of paraffin sections of biological tissue, especially for molecular pathology studies is disclosed. In the process, the tissue sample is simultaneously fixed, dehydrated and cleared in a first step, subsequently dehydrated and cleared in a second step and infiltrated with an inert specimen matrix in a third step. The specimen can then be further embedded in a casting supporting matrix according to the standard procedures followed by any local pathology or research laboratory. A kit and a processing station for automating paraffin embedding of a tissue sample suitable for histopathological and molecular analysis is also described. A bio-indicator system is described for measuring the degree of crosslinking. A tissue sample holding means or a vial which includes a tissue sample holding means provided with a data logging device capable of registering and transmitting data regarding the sample and conditions where the sample was processed is also disclosed.

Apparatus and methods for automatically staining or treating multiple tissue samples mounted on slides are provided, in which the slides and reagent bottles are held in fixed position, and the reagent, wash and coverslipping solutions brought to the slides. Alternatively, the slides are held in fixed position, while the reagent, wash and coverslipping solutions brought to the slides.

The invention provides a formaldehyde-free fixative for a tissue sample, which comprises the following ingredients in parts by volume: 710-790 parts of ethanol, 20-40 parts of glacial acetic acid, 10-30 parts of acetone, 40-60 parts of polyhydric alcohol, 40-60 parts of trichloroacetic acid (TDA), 40-60 parts of surface active agent and 40-60 parts of solubilizing agent. The formaldehyde-free fixative is a nontoxic and innocuous chemical reagent; after being proved by cellular morphological experiments, immunohistochemical experiments, molecular pathological experiments and nucleic acid extraction experiments, the formaldehyde-free fixative has relatively comprehensive fixing effect, can replace the formaldehyde and be used in related pathological experiments, thereby fixing the tissue sample.

The invention belongs to the technical field of molecular pathology and immunology and in particular relates to a construction method of recombinant plasmid of PD-L1 (programmed death-ligand 1) in chicken peripheral blood mononuclear lymphocytes, a real-time gene abundance detection method and application of the detection method. The construction and detection methods comprise the following steps: acquiring total RNA (ribonucleic acid) of chicken lymphocytes and carrying out reverse transcription on the total RNA to obtain cDNA (complementary deoxyribonucleic acid); carrying out common PCR (polymerase chain reaction) amplification on a PD-L1 target gene segment, detecting the target gene segment through agarose gel electrophoresis and recovering and purifying the target gene segment; connecting the PD-L1 target gene segment with a pMD18-T carrier, transforming the product into a competent cell DH5alpha and extracting the recombinant plasmid; carrying out sequencing analysis after cloning and screening, selecting positive plasmid with the same sequence as the target gene segment as standard plasmid and drawing a standard curve according to the copy concentration; and detecting the gene abundance of the PD-L1 according to fluorescence signal change and the standard curve. The real-time PD-L1 gene abundance detection method has the advantages of high detection flux, high sensitivity, strong specificity, simplicity and convenience in operation, low cost, accuracy in quantification and the like.

The invention belongs to the technical field ofmolecular pathology andimmunology, and relates to construction of pig peripheral bloodmononuclear lymphocytePD-1 (programmed death-1) recombinantplasmids, a real-time gene abundance detection method and an application of the method. TotalRNA of pig peripheral bloodmononuclear lymphocytes is collected and reverselytranscribed into cDNA (complementary DNA); PD-1 target gene fragmentsare amplified through a general PCR (polymerase chain reaction), detected throughagarose gel electrophoresis, recovered and purified; the PD-1 target gene fragments are connected with pMD18-T carriers and converted into competent cells DH5alpha, and the recombinantplasmids are extracted; sequencing analysis is performed after cloning and screening, positive plasmids with the same sequence as the targetgene fragments are selected to serve as standard plasmids, and a standard curve is drawn according to the copy concentration; thePD-1 gene abundance is measured according to fluorescence signal changes and the standard curve. The real-time pig PD-1 gene abundancedetection method has the advantages of high detection throughput, high susceptibility, high specificity, convenience in operation, low cost, accuracy in quantification and the like.

The invention relates to a detection method and chip for a susceptibility gene of dilatant and hypertrophic cardiomyopathy. Based on a target region capture high-throughput sequencing technology, a group of specific and effective gene set associated with DCM/HCM cardiovascular disease is selected and is subjected to high-throughput capture and sequencing analysis by a self-developed probe library-building capture process and analysis software, so as to find out variation conditions of genetic level cardiovascular disease-related genes, especially DCM/HCM genes and the like, by gene means to screen the susceptibility gene. The screening result refers to the guidelines of the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) to interpret variations. Compared with conventional high-throughput sequencing, a kit has the advantages of high pertinence, low cost, fast flow and the like.

The invention discloses an Alzheimer disease (AD) pathogenic gene and an application thereof, which belong to the technical field of molecular pathology. The cDNA nucleotide sequence of the gene is represented by SEQ ID NO:1. The invention also relates to a recombinant vector containing the Alzheimer disease pathogenic gene, a recombinant cell containing the recombinant vector, a coding protein of the Alzheimer disease pathogenic gene, and an exon of the Alzheimer disease pathogenic gene. The detection of the gene with the Alzheimer disease pathogenic gene exon can be used in gene molecular diagnosis of an AD patient, or in determining pathogenic risk prediction of AD patient relatives. The invention assists in providing an important clue for the AD pathogenic mechanism. An exon vector containing the Alzheimer disease pathogenic gene can be used for preparing an AD cell or an animal model.

The invention belongs to the technical field of molecular pathology and immunology and in particular relates to a construction method of recombinant plasmid of PD-1 (programmed death-1) in chicken peripheral blood mononuclear lymphocytes, a real-time gene abundance detection method and application of the detection method. The construction and detection methods comprise the following steps: acquiring total RNA (ribonucleic acid) of chicken lymphocytes and carrying out reverse transcription on the total RNA to obtain cDNA (complementary deoxyribonucleic acid); carrying out common PCR (polymerase chain reaction) amplification on a PD-1 target gene segment, detecting the target gene segment through agarose gel electrophoresis and recovering and purifying the target gene segment; connecting the PD-1 target gene segment with a pMD18-T carrier, transforming the product into a competent cell DH5alpha and extracting the recombinant plasmid; carrying out sequencing analysis after cloning and screening, selecting positive plasmid with the same sequences as the target gene segment as standard plasmid and drawing a standard curve according to the copy concentration; and detecting the gene abundance of the PD-1 according to fluorescence signal change and the standard curve. The real-time PD-1 gene abundance detection method has the advantages of high detection flux, high sensitivity, strong specificity, simplicity and convenience in operation, low cost, accuracy in quantification and the like.

The invention discloses a kit for extracting DNA from a biological tissue sample by a paraffin imbedding method. The kit comprises a deparaffinating solvent A, a buffer solution B, protein digestive fluid C, a nucleic acid purification column D and eluate E, wherein the deparaffinating solvent A contains SDS, NP40 and NaCL, and the buffer solution B contains EDTA, NaCL and SDS. According to the kit for extracting the DNA from the biological tissue sample by the paraffin imbedding method, disclosed by the invention, the quality of the extracted DNA fully meets the requirements of molecular pathology detection, and the extracted DNA is high in content.

The invention relates to application of B7H4 in preparation of an endometrial cancer molecular typing reagent and system. The method comprises the following steps: firstly, screening out a POLE mutant by a sequencing method; detecting four kinds of mismatch repair proteins on a specimen without pathogenic mutation, and screening out a dMMR type; screening out a p53 mutant from a sample without dMMR by means of immunohistochemical detection of p53 protein; if the p53 mutation does not exist, determining that the p53 mutation is an NSMP type; and for specimens for interpreting the dMMR type and the NSMP type, detecting expression of protein B7H4 through immunohistochemistry, wherein B7H4 coloring in more than 1% of tumor cells is judged as a B7H4 expression type, and B7H4 non-expression types are judged in the rest. According to the invention, endometrial cancer is divided into a POLE mutant type, a B7H4 expression type, a B7H4 non-expression type and a p53 mutant type; and the improved molecular typing is still based on molecular pathology, has the characteristics of relative objectiveness, high repeatability and clinical feasibility of the existing molecular typing, but has higher predictive ability than the existing model, and is beneficial to avoiding excessive treatment and insufficient treatment.

The invention belongs to the field of molecular pathology, and relates to a hereditary medullispinal cerebellar ataxia related gene (mutant), particularly a hereditary medullispinal cerebellar ataxia related gene of which the amino acid sequence is disclosed as SEQ ID NO:7 or SEQ ID NO:9, and more particularly a hereditary medullispinal cerebellar ataxia related gene of which the nucleic acid sequence is disclosed as SEQ ID NO:6 or SEQ ID NO:8. The invention also relates to a recombinant vector containing the medullispinal cerebellar ataxia related gene, a recombinant cell containing the recombinant vector, and a coding protein of the medullispinal cerebellar ataxia related gene. Besides, the invention also relates to an exon of the hereditary medullispinal cerebellar ataxia related gene and a coding protein thereof. The invention provides references for auxiliary molecular diagnosis, molecular typing, prenatal diagnosis, drug target selection and clinical treatment of the hereditary medullispinal cerebellar ataxia.

This application belongs to the technical field of biology, and discloses a kit and method for detecting programmed cell death 1 ligand 1 (PD-L1) mRNA on tissue. The kit disclosed by the invention comprises probe sets shown by SEQ ID NO. 1-91. The kit has simple composition, remedies the current situation that immunohistochemical effective antibodies are lacking, eliminates the shortcomings of a fluorescence in situ hybridization (FISH) technology, and greatly expands the field of detection of molecular pathology.